K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature

doi:10.1016/j.lungcan.2016.01.002

Lung Cancer

Volume 93, March 2016, Pages 55-58

https://doi.org/10.1016/j.lungcan.2016.01.002 Get rights and content

Highlights

•
K-RAS and ALK alterations in NSCLC may co-exist.
•
K-RAS mutations confer crizotinib resistance to ALK-rearranged NSCLC.
•
K-RAS appears a strong negative predictive marker in oncogenic-driven NSCLC.

Abstract

The paradigm of mutually exclusive alterations among oncogenic drivers in non-small-cell lung cancer (NSCLC) is challenged by the increasing evidence of detection of two or more driver alterations in the same tumor using highly-sensitive molecular assays. We report here two cases of ALK-rearranged adenocarcinomas harboring concomitant exon 2 K-RAS mutations (G13D and Q61H). The patients, a 49-year-old smoker man and a 59-year-old non-smoking woman, experienced a rapid disease progression and primary resistance to crizotinib. Search for similar cases in the literature reveals that concomitant K-RAS mutations and ALK rearrangement occur in a subset of NSCLC and seems to lead to resistance to crizotinib. Among 8 similar cases receiving crizotinib previously reported (4 in first line and 4 in second line), 1 had a partial response, 1 stable disease and 6 disease progression. One patient still had progression disease when switching to ceritinib. At the end, K-RAS mutations seem to represent a negative predictive marker in ALK-rearranged adenocarcinomas treated with ALK inhibitor.

Introduction

Anaplastic Lymphoma Kinase (ALK) gene rearrangement was identified in about 5% of non-small-cell lung cancer (NSCLC) patients, often characterized by adenocarcinoma (ADC) histotype, younger age and no or light-smoking history. The vast majority of these cases are wild-type for Epidermal Growth Factor Receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (K-RAS) genes analysis [1], [2]. ALK-positive adenocarcinomas are highly responsive to the triple ALK, c-MET, ROS1 inhibitor crizotinb in about 65% of cases [3], [4]. The median clinical response is of about 10 months, but relapse inevitably occurs and secondary resistance is generally due to occurrence of ALK mutations, ALK gene amplification and activation of escape signalling pathways [5]. No consisting data are reported concerning the mechanisms leading to primary resistance in 30–40% of ALK-positive patients unresponsive to crizotinib [6], [7]. Novel and more potent ALK-inhibitors, namely ceritinib, alectinib and brigatinib, have been developed to overcome primary or acquired resistance to crizotinib [6]. The concomitant occurrence of K-RAS mutations and ALK rearrangement have been recently described in a subset of adenocarcinomas, generally leading to primary resistance to crizotinib [7], [8], [9], [10], [11], [12], [13]. We report here two additional patients, a 49-year-old smoker male and a 59-year-old non-smoking woman, with advanced pulmonary adenocarcinoma harboring concomitant K-RAS mutations (G13D; Q61H) and ALK rearrangement experiencing rapid disease progression on chemotherapy and crizotinib. No ALK gene mutations were detected. The role of the “undruggable” KRAS mutations as negative predictive marker [14] in ALK rearranged adenocarcinoma is discussed.

Section snippets

Case 1

In September 2014, a 49-year-old man, heavy smoker presented to our Institution with seizures. CT and RM-brain imaging showed 2 frontal and a cerebellar metastatic lesions. Chest-CT revealed a solid mass of the right upper lobe and enlarged mediastinal lymph nodes. A bronchial biopsy was performed and a diagnosis of primary pulmonary adenocarcinoma was made (stage IV according to the 7th AJCC/UICC tumor staging system) (Fig. 1). At immunohistochemistry (IHC), tumor cells were positive with

Discussion

About 65% of ALK-rearranged lung adenocarcinomas respond to crizotinib and the occurrence of ALK mutations seems to represent the most important mechanism of secondary resistance [3], [4], [5], [6]. However, few data are available concerning primary resistance and the presence of concurrent gene alterations in ALK-rearranged tumors has been poorly investigated [5], [6], [7].

We report here 2 cases of ALK-rearranged (both positive by FISH assay, while 1 positive and 1 negative by IHC)

Conflict of interest

The authors declare no conflict of interest.

References (24)

A.T. Shaw et al.
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Lancet Oncol.
(2011)
F. Cabillic et al.
Parallel FISH and immunohistochemistry studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances
J. Thorac. Oncol.
(2014)
A.G. Stephen et al.
Dragging ras back in the ring
Cancer Cell
(2014)
O. Fiala et al.
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Cancer Genet.
(2013)
A.T. Shaw et al.
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
J. Clin. Oncol.
(2009)
J.F. Gainor et al.
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer
Clin. Cancer Res.
(2013)
E.L. Kwak et al.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
N. Engl. J. Med.
(2010)
C.M. Lovly et al.
Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies
Clin. Cancer Res.
(2014)
L. Cameron et al.
Treatment of ALK-rearranged non-small cell lung cancer: recent progress and future directions
Drugs
(2015)
R.C. Doebele et al.
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
Clin. Cancer Res.
(2012)

H.H. Rossing et al.

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

BMC Res. Notes

(2013)

J. Jürgens et al.

Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients

Future Oncol.

(2014)

Cited by (39)

EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors
2021, Cancer Genetics
The ALK inhibitors are promising therapeutic agents against lung cancer harboring ALK fusion genes and are currently under development up to the third generation. However, its therapeutic effects are reported to be affected by differences in ALK variants and co-occurrent mutations. Materials and Methods; We experienced an autopsy case of an ALK-positive lung cancer patient who showed primary resistance to three generations of ALK inhibitors. The poor survival time of the case was 14 months. To reveal the mechanism of primary resistance to three generations of ALK inhibitors, we performed next generation sequencing for 12 specimes obtained from an autopsy with covering whole exons of 53 significantly mutated, lung cancer-associated genes and amplicon-based target RNA sequenceing for the ALK fusion gene. The NGS analysis revealed a rare variant.3 of ALK fusion, in which 30 bp of base was inserted at the end of ALK intron.19 and was associated with EML exon.6 [E6_ins30A20] and a co-occurrent oncogenic PIK3CA E542K mutation in all specimens. Structural analysis of the fusion protein ALK [E6_ins30A20] showed no interferance with the binding of ALK inhibitors to the kinase domain. The NGS analysis of primary and metastatic lesions obtained from an autopsy revealed a co-occurrent oncogenic PIK3CA E542K mutation in all specimens. The constitutive activation of PI3K-Akt signal by PIK3CA E542K mutation occurred downstream of ALK signaling pathway, could lead to primary resistance to ALK inhibitors in all generations.
Molecular and therapeutic bases of cancer
2021, Oncological Functional Nutrition: Phytochemicals and Medicinal Plants
Develop, growth and death of multicellular organisms are regulated by intricated pathways with several effectors. Over the studies of the past decades, it is clear that molecular biology has contributed to find an infinitude of molecules that take part in different mechanisms such as: gene replication, gene transcription and gene translation. In the same route, molecular biology either found that these molecules are not lonely effectors in these mechanisms. Furthermore, the same proteins that develop multicellular organisms or repair their bodies, take place in malignancies growth and cancer progression. Many of those molecules are direct or indirectly involved to other cellular mechanism such cell microenvironment and inflammation. This chapter look for a landscape view of cancer, introducing new perspectives about malignant transformation and complementary treatments.
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
2020, Lung Cancer
Citation Excerpt :
Information on co-occurring genetic alterations is not available in these patients, but it is likely some patients with a smoking history have additional mutations, rendering the ALK inhibitors less beneficial. There is evidence that concomitant oncogenic mutations, related to tobacco use, may cause primary resistance or be negatively prognostic in patients receiving ALK inhibitors [40–43]. There appeared to be a greater degree of benefit with second-generation ALK inhibitors compared to crizotinib in patients with intracranial disease, although this difference did not reach significance.
No overall survival (OS) benefit has been reported from a mature randomized trial with the use of ALK inhibitors. We conducted a systematic review and meta-analysis to assess the efficacy of ALK inhibitors compared to chemotherapy (ALK vs. chemo) and 2nd generation ALK inhibitors compared to 1 st generation ALK inhibitors (ALK-2 G vs. ALK-1 G).
The electronic databases Medline (PubMed), EMBASE, and the Cochrane Database of Systematic Reviews were searched for relevant randomized trials. Pooled hazard ratios (HR) for OS and progression free survival (PFS), and pooled risk ratios for objective response rates (ORR) and toxicity were meta-analyzed using the generic inverse variance and the Mantel-Haenszel methods. To account for between-studies heterogeneity, random-effect models were used. Subgroup analyses compared PFS by gender, smoking status, brain metastases, race and age.
Six trials were included in the analysis of ALK vs. chemo and four in the analysis of ALK-2 G vs. ALK-1 G. Treatment with ALK inhibitors improved OS compared to chemotherapy (HR: 0.84, 95 %CI 0.72−0.97) while a trend toward a better OS was seen with ALK-2 G vs. ALK-1 G (HR: 0.66, 95 %CI 0.43–1.02). PFS was improved with ALK vs. chemo and ALK-2 G vs. ALK-1 G (HR: 0.44, 95 %CI 0.35−0.54 and HR: 0.38, 95 %CI-0.29−0.51, respectively). ORR was improved with ALK vs. chemo and ALK-2 G vs. ALK-1 G. No difference in toxicity was observed.
This meta-analysis is the first, to our knowledge, to report an OS and PFS benefit with the use of ALK inhibitors compared to chemotherapy from randomized trial data. A trend toward a better OS was also seen with ALK-2 G vs. ALK-1 G and this is likely because of crossover effects and limited OS follow-up. Longer follow up and further research are warranted to directly compare ALK inhibitor sequences and to understand the outcomes of second generation ALK inhibitors as initial therapy.
RASSF1A: A promising target for the diagnosis and treatment of cancer
2020, Clinica Chimica Acta
Citation Excerpt :
There is a close association between RAS mutations and drug resistance in standard therapies [142,143]. Some case reports have suggested that KRAS mutations may lead to resistance to anaplastic lymphoma kinase inhibitors, such as crizotinib, in NSCLC patients [144]. In addition, many lung cancer patients may be resistant to reactive oxygen species 1 inhibitors and eventually relapse due to the activation of RAS [145].
The Ras association domain family 1 isoform A (RASSF1A), a tumor suppressor, regulates several tumor-related signaling pathways and interferes with diverse cellular processes. RASSF1A is frequently demonstrated to be inactivated by hypermethylation in numerous types of solid cancers. It is also associated with lymph node metastasis, vascular invasion, and chemo-resistance. Therefore, reactivation of RASSF1A may be a viable strategy to block tumor progress and reverse drug resistance. In this review, we have summarized the clinical value of RASSF1A for screening, staging, and therapeutic management of human malignancies. We also highlighted the potential mechanism of RASSF1A in chemo-resistance, which may help identify novel drugs in the future.
An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer
2019, Translational Oncology
We developed and characterized a next-generation sequencing (NGS) technology for streamlined analysis of DNA and RNA using low-input, low-quality cancer specimens. A single-workflow, targeted NGS panel for non–small cell lung cancer (NSCLC) was designed covering 135 RNA and 55 DNA disease-relevant targets. This multiomic panel was used to assess 219 formalin-fixed paraffin-embedded NSCLC surgical resections and core needle biopsies. Mutations and expression phenotypes were identified consistent with previous large-scale genomic studies, including mutually exclusive DNA and RNA oncogenic driver events. Evaluation of a second cohort of low cell count fine-needle aspirate smears from the BATTLE-2 trial yielded 97% agreement with an independent, validated NGS panel that was used with matched surgical specimens. Collectively, our data indicate that broad, clinically actionable insights that previously required independent assays, workflows, and analyses to assess both DNA and RNA can be conjoined in a first-tier, highly multiplexed NGS test, thereby providing faster, simpler, and more economical results.
RAS-mediated oncogenic signaling pathways in human malignancies
2019, Seminars in Cancer Biology
Abnormally activated RAS proteins are the main oncogenic driver that governs the functioning of major signaling pathways involved in the initiation and development of human malignancies. Mutations in RAS genes and or its regulators, most frequent in human cancers, are the main force for incessant RAS activation and associated pathological conditions including cancer. In general, RAS is the main upstream regulator of the highly conserved signaling mechanisms associated with a plethora of important cellular activities vital for normal homeostasis. Mutated or the oncogenic RAS aberrantly activates a web of interconnected signaling pathways including RAF-MEK (mitogen-activated protein kinase kinase)-ERK (extracellular signal-regulated kinase), phosphoinositide-3 kinase (PI3K)/AKT (protein kinase B), protein kinase C (PKC) and ral guanine nucleotide dissociation stimulator (RALGDS), etc., leading to uncontrolled transcriptional expression and reprogramming in the functioning of a range of nuclear and cytosolic effectors critically associated with the hallmarks of carcinogenesis. This review highlights the recent literature on how oncogenic RAS negatively use its signaling web in deregulating the expression and functioning of various effector molecules in the pathogenesis of human malignancies.

View all citing articles on Scopus

View full text

K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature

Highlights

Abstract

Introduction

Section snippets

Case 1

Discussion

Conflict of interest

Lancet Oncol.

J. Thorac. Oncol.

Cancer Cell

Cancer Genet.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

J. Clin. Oncol.

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer

Clin. Cancer Res.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

N. Engl. J. Med.

Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies

Clin. Cancer Res.

Treatment of ALK-rearranged non-small cell lung cancer: recent progress and future directions

Drugs

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer

Clin. Cancer Res.

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

BMC Res. Notes

Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients

Future Oncol.